Our News

Affinia Therapeutics and Forge Biologics Announce AAV cGMP Manufacturing Partnership to Advance Affinia Therapeutics’ Pipeline of Next-Generation Gene Therapies to the Clinic

ESGCT 2024: Affinia’s Proprietary AAV Plasmid Design Produces Industry Leading Manufacturability of Novel and WT Capsids

ESGCT 2024: In Vitro Binding to Human and NHP Orthologs of Candidate Receptors Identify Novel Systemically Delivered AAVs With Enhanced CNS Tropism

ESGCT 2024: A Novel AAV Gene Therapy for Treatment of MYBPC3 Hypertrophic cardiomyopathy

ESGCT 2024: A Novel AAV Gene Therapy for Treatment of BAG3 Dilated Cardiomyopathy

Affinia Therapeutics to Highlight New Data on Genetic Cardiomyopathy Programs and BBB-Penetrant Capsids Leveraging Novel Receptors at the European Society of Gene & Cell Therapy 2024 31st Annual Congress

Discover what it’s like to be an Affinian

Changing the world for patients – powered by science